Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Dementia (2)
- Alcohol abuse (1)
- Alzheimer's disease (1)
- Amyloid (1)
- Animals (1)
-
- Breast Neoplasms (1)
- Breast cancer (1)
- Cell Line, Tumor (1)
- Cerebrovascular disease (1)
- Cognitive decline (1)
- Diabetes complications (1)
- Diabetes mellitus (1)
- Diabetic brain injury (1)
- Disease Models, Animal (1)
- Disease Progression (1)
- ERBB2 (1)
- Ethanol (1)
- Female (1)
- Humans (1)
- MCF-7 Cells (1)
- Mammary Neoplasms, Experimental (1)
- Mice (1)
- Mice, Transgenic (1)
- Obesity (1)
- Phosphoproteins (1)
- Receptor, ErbB-2 (1)
- STARD10 (1)
- Transfection (1)
- Type 2 diabetes mellitus (1)
Articles 1 - 3 of 3
Full-Text Articles in Entire DC Network
Contributing Factors To Diabetic Brain Injury And Cognitive Decline, Nirmal Verma, Florin Despa
Contributing Factors To Diabetic Brain Injury And Cognitive Decline, Nirmal Verma, Florin Despa
Pharmacology and Nutritional Sciences Faculty Publications
The link of diabetes with co-occurring disorders in the brain involves complex and multifactorial pathways. Genetically engineered rodents that express familial Alzheimer's disease-associated mutant forms of amyloid precursor protein and presenilin 1 (PSEN1) genes provided invaluable insights into the mechanisms and consequences of amyloid deposition in the brain. Adding diabetes factors (obesity, insulin impairment) to these animal models to predict success in translation to clinic have proven useful at some extent only. Here, we focus on contributing factors to diabetic brain injury with the aim of identifying appropriate animal models that can be used to mechanistically dissect the …
Diabetes-Related Amylin Dyshomeostasis: A Contributing Factor To Cerebrovascular Pathology And Dementia, Han Ly, Florin Despa
Diabetes-Related Amylin Dyshomeostasis: A Contributing Factor To Cerebrovascular Pathology And Dementia, Han Ly, Florin Despa
Pharmacology and Nutritional Sciences Faculty Publications
Type 2 diabetes (T2D) increases the risk for cerebrovascular disease (CVD) and dementia. The underlying molecular mechanisms remain elusive, which hampers the development of treatment or/and effective prevention strategies. Recent studies suggest that dyshomeostasis of amylin, a satiety hormone that forms pancreatic amyloid in patients with T2D, promotes accumulation of amylin in cerebral small blood vessels and interaction with Alzheimer's disease (AD) pathology. Overexpression of human amylin in rodents (rodent amylin does not form amyloid) leads to late-life onset T2D and neurologic deficits. In this Review, we discuss clinical evidence of amylin pathology in CVD and AD and identify critical …
Star-Related Lipid Transfer Protein 10 (Stard10): A Novel Key Player In Alcohol-Induced Breast Cancer Progression, Andrea Floris, Jia Luo, Jacqueline A. Frank, Jennifer Zhou, Sandro Orrù, Michela Biancolella, Sabina Pucci, Augusto Orlandi, Paolo Campagna, Antonella Balzano, Komal Ramani, Maria Lauda Tomasi
Star-Related Lipid Transfer Protein 10 (Stard10): A Novel Key Player In Alcohol-Induced Breast Cancer Progression, Andrea Floris, Jia Luo, Jacqueline A. Frank, Jennifer Zhou, Sandro Orrù, Michela Biancolella, Sabina Pucci, Augusto Orlandi, Paolo Campagna, Antonella Balzano, Komal Ramani, Maria Lauda Tomasi
Pharmacology and Nutritional Sciences Faculty Publications
Background: Ethanol abuse promotes breast cancer development, metastasis and recurrence stimulating mammary tumorigenesis by mechanisms that remain unclear. Normally, 35% of breast cancer is Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2)-positive that predisposes to poor prognosis and relapse, while ethanol drinking leads to invasion of their ERBB2 positive cells triggering the phosphorylation status of mitogen-activated protein kinase. StAR-related lipid transfer protein 10 (STARD10) is a lipid transporter of phosphatidylcholine (PC) and phosphatidylethanolamine (PE); changes on membrane composition of PC and PE occur before the morphological tumorigenic events. Interestingly, STARD10 has been described to be highly expressed in 35–40% of ERBB2-positive breast …